Brief: Nasdaq Rejects Novakand's Application For Continued Listing
24/02/2026 12:17
Feb 24 (Reuters) - Novakand Pharma AB NOVKAN.ST: NASDAQ REJECTS NOVAKAND'S APPLICATION FOR CONTINUED LISTING REVERSE ACQUISITION CANCELED, EXTRAORDINARY MEETING ON MARCH 12 CANCELED MUST TAKE MEASURES WITHIN FOUR MONTHS TO AVOID DELISTING Source text: ID:nMFN1czbpy Further company coverage: NOVKAN.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Novakand Pharma AB
See all newsBrief: Nasdaq Decides To Delist Novakand From First North Growth Market
Brief: Novakand Pharma Extends Peter Selin's CEO Employment
Brief: Novakand Board Proposes New Business Direction, Relisting
Brief: Novakand Pharma Evaluates Options After Decision Not To Execute Reverse Take Over
Brief: Nasdaq Rejects Novakand's Application For Continued Listing